Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma to delist from AQSE and go private to refocus on drug development
Ananda Pharma PLC has announced plans to withdraw from the AQSE Growth Market and re-register as a private company, citing the high cost of being publicly listed, regulatory complexity and
Ananda Pharma plc (AQSE: ANA, OTC: ANANF) Webinar Presentation Release
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate
Ananda Pharma plc (AQSE: ANA) Appointment of Commercial Adviser
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as
An Introduction to Ananda Developments
Finance Director Jeremy Sturgess-Smith introduces Ananda Developments, outlining the company’s mission, strategic focus, and what makes it distinct within the CBD and drug development sectors.
Redx Pharma quits London stock market over its low valuation
Redx Pharma has announced its departure from the London stock market due to a perceived undervaluation, marking it as the second British pharmaceutical firm in the past week to reveal
Evgen Pharma (AIM:EVG) welcomes a new chairman and Chief Financial Officer (CFO).
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Omega Diagnostics Gp (AIM:ODX) Directorate Change
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that Chris Lea, Group Finance Director of the Company, will be stepping down as
Evgen Pharma (AIM:EVG) celebrates the potential new formulation of its leading candidate.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma (AIM:EVG) shifts focus towards more lucrative collaborations as their partnership with JuvLife concludes.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
Futura Medical PLC (AIM:FUM) MED3000 Granted US FDA Approval for OTC Sale
Futura’s Fast-Acting Topical Gel for the Treatment of Erectile Dysfunction Granted Marketing Authorisation by the US FDA for Over-the-Counter Sale
Clinical Trial to Employ ANGLE Technology for Cancer Treatment
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.